InSysBio to upgrade its SbmlViewer application

NEWS
Press-Release
May 19, 2021

May 19, 2021

[Moscow – 19.05.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches the new version (0.3.0) of its SbmlViewer open project. Generally, SbmlViewer is a tool for fast and easy reading and transformation of biological models written in SBML format. It allows reading SBML models without any software installation via the web browser.

InSysBio constantly moves forward in its software advancement for both internal and external usage. Thus, SbmlViewer application is being constantly upgraded and got some new features over recent months.

Evgeny Metelkin, Head of Product Development, comments on the update, ”Now SbmlViewer supports the Antimony format which is another human-readable modeling language for systems biology. In addition, the new version has substantial updates to Heta code representation". Moreover, the bug of true/false in the Heta format and logical operators in Heta export have been fixed.

Its usage is secure for a code since SbmlViewer never uploads your files to the server and all transformations are performed locally in your browser. SbmlViewer is extremely helpful in the following cases:

  • a user needs to share a model in human readable and compact format;
  • a user cannot install his favorite tool to read and check some SBML file;
  • some software cannot read some specific SBML elements but the file includes them;
  • a user has some errors when importing SBML and checking the model code.

SbmlViewer is an open project located on GitHub

For more information, please visit sv.insysbio.com

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

May 2025
MoTuWeThFrSaSu
   
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1. 15 May 2025 15:07 15th InSysBio’s Annual Internal Scientific Meeting InSysBio held its 15th Annual Internal Scientific Meeting. The Meeting traditionally passed in warm, friendly atmosphere and the discussion was efficient and uniting.
16
17
18
19
20
21
1. 21 May 2025 16:55 InSysBio to take part in PAGE 2025 InSysBio announces its participation in the Thirty-third PAGE Meeting which is to be held from 4-6 June, 2025, at the Thessaloniki Concert Hall in Thessaloniki, Greece. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #10 in the upper foyer and 2 posters in frames of the Meeting
22
23
24
25
26
27
28
29
30
1. 30 May 2025 15:23 InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics The new article “Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data” has been recently published in CPT: Clinical Pharmacology & Therapeutics
31
 
Upcoming Events
Tags
Latest News
03.06
InSysBio to present Integration of Cytocon DB and fIVE DB with Heta for QSP modeling
30.05
InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics
15.05
15th InSysBio’s Annual Internal Scientific Meeting
09.04
InSysBio to release a new version of LikelihoodProfiler.jl
31.03
InSysBio to launch Immune Response Template version 3.7.0 for QSP modeling